July 2026– date –
-
Exosome Clinical Trials Hit ~90 Globally in 2026: Advancing Regenerative Medicine, Diagnostic Biomarkers, and Drug Delivery
OmniGenix USA Overview A new peer-reviewed analysis in 2026 reveals approximately 90 exosome-related human clinical trials registered globally, showcasing diverse applications from cancer diagnostics to joint repair. Exosomes are being i... -
Penn Medicine’s AI Framework Uncovers Novel GPNMB Target for CAR T-cell Therapy, Advancing Solid Tumor Treatment
Penn Medicine USA Overview Researchers at Penn Medicine have developed an innovative artificial intelligence (AI)-powered framework to efficiently identify novel target antigens for CAR T-cell therapy. This AI framework successfully demo... -
GCAR1: Engineered CAR T-Cells Breakthrough Against Solid Tumors, Showing Promise in Sarcoma
News-Medical.net (University of Calgary発表) Canada Overview Researchers from the University of Calgary and McMaster University have developed GCAR1, an experimental CAR T-cell therapy targeting a novel glycoprotein uniquely expressed in... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C... -
Europe’s Biotech Vanguard: Automated, Closed Systems Drive Next-Gen CGT Manufacturing and Decentralized Access
PharmTech.com ヨーロッパ Overview European biotechnology firms are pioneering next-generation manufacturing technologies for cell and gene therapies (CGT), centered on automated, closed systems. These innovations, exemplified by companie... -
FDA RMAT Designations Hit Record 48 in 2025, Signaling CGT Pipeline Maturity and Market Acceleration
Pharmaceutical Technology UK Overview FDA Regenerative Medicine Advanced Therapy (RMAT) designations surged from 2024, reaching a record 48 in 2025, according to Pharmaceutical Technology analysis. This unprecedented increase reflects th... -
China Grants World’s First Solid Tumor CAR-T Approval for Satri-cel in Advanced Gastric Adenocarcinoma
Fierce Biotech USA Overview China's National Medical Products Administration (NMPA) has approved CARsgen Therapeutics' solid tumor CAR-T cell therapy, satri-cel, for HER2-negative, Claudin18.2-positive advanced gastric and gastroesophage... -
USC Scientists Engineer ‘Endless Supply’ of iPSC-Derived Immune Cell Precursors to Supercharge Cancer Immunotherapy
ScienceDaily (University of Southern California) USA Overview University of Southern California (USC) scientists have successfully cultured a virtually limitless supply of immune cell precursors, inspired by induced pluripotent stem cell... -
FDA RMAT Designations Reach 162 Total: Rocket Pharmaceuticals and CRISPR Therapeutics Lead
BioInformant USA Overview The FDA's publicly announced Regenerative Medicine Advanced Therapy (RMAT) designations have reached a total of 162, with approximately half of all RMAT applications being approved, according to BioInformant dat... -
FDA Approves Allogeneic Cell Therapy TREGZI for GVHD; New Advanced Cell Therapy Association Launches in Europe
RegMedNet UK Overview The FDA has approved Orca Bio's allogeneic cell therapy TREGZI (Orc-T®) for graft-versus-host disease (GVHD), based on positive Phase 3 Precision-T trial results, aiming to mitigate GVHD and reconstruct immunity. Si...
